RUBY-3 findings support povetacicept’s ability to induce remission, reduce UPCR, stabilize renal function, and resolve hematuria in patients with IgAN.
Preliminary data from the SPARTAN study were presented at ASN Kidney Week 2023, demonstrating sparsentan’s impact on proteinuria and total body water over time.